{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"5"}]}],"title":"Anemia Grade 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"26"}]}],"title":"Anemia Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"7"}]}],"title":"Anemia Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"}]}],"title":"Anemia Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Anemia Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"}]}],"title":"Anemia Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"9"}]}],"title":"Lymphocytes count decreased Grade 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"7"}]}],"title":"Lymphocytes count decreased Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"10"}]}],"title":"Lymphocytes count decreased Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"9"}]}],"title":"Lymphocytes count decreased Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}],"title":"Lymphocytes count decreased Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"9"}]}],"title":"Lymphocytes count decreased Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"}]}],"title":"Neutrophils count decreased Grade 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"0"}]}],"title":"Neutrophils count decreased Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}]}],"title":"Neutrophils count decreased Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"1"}]}],"title":"Neutrophils count decreased Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"2"}]}],"title":"Neutrophils count decreased Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"9"}]}],"title":"Neutrophils count decreased Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"35"}]}],"title":"Platelets count decreased Grade 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"}]}],"title":"Platelets count decreased Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}]}],"title":"Platelets count decreased Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Platelets count decreased Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Platelets count decreased Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"}]}],"title":"Platelets count decreased Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"36"}]}],"title":"White blood cell decreased Grade 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"3"}]}],"title":"White blood cell decreased Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"1"}]}],"title":"White blood cell decreased Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"}]}],"title":"White blood cell decreased Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}]}],"title":"White blood cell decreased Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"}]}],"title":"White blood cell decreased Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"140"},{"groupId":"OG002","value":"44"}],"units":"Participants"}],"description":"Blood samples were collected to assess hematology parameters. Adverse events are graded on a scale from 0 to 4 based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with Grade 0 being normal Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.","groups":[{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with Adagrasib tablet or capsule orally at a starting dose of 600 mg twice a day (BID).","id":"OG000","title":"Adagrasib"},{"description":"Participants with Non Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation and who have received prior therapy with a platinum-based regimen and an immune checkpoint inhibitor were administered in 3-week cycle with intravenous infusion of Docetaxel at 75 mg/m\\^2 over 1 hour or according to institutional practices.","id":"OG001","title":"Docetaxel"},{"description":"Eligible participants receiving Docetaxel earlier in the study switched to Adagrasib based on physician decision. Participants were administered with Adagrasib orally at a starting dose of 600 mg twice a day (BID).","id":"OG002","title":"Crossover Adagrasib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population included all the participants who received at least one dose of the study drug. Docetaxel arm do not include adverse events after initiation of crossover Adagrasib treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of treatment (Day 1) till 28 days after last dose (Up to approximately 110 weeks)","title":"Number of Participants With Maximum CTCAE Grade Laboratory Abnormality in Hematology Parameters","type":"SECONDARY","unitOfMeasure":"Participants"}